Our results show that the consumption of either NPJ or HPJ protected against DNA damage and lipid peroxidation, modified several antioxidant enzymes, and reduced body weight in overweight or obese nonsmoking adults. Only blood pressure and SOD activity were influenced differently by the different flavanone supplementations. This trial was registered at clinicaltrials.gov as NCT01290250.

We designed a new panel of biomarkers to differentiate the intake of OJs containing different doses of polyphenols. On the other hand, the consumption of an OJ with a high content of flavanones improved oxidative stress and inflammatory biomarkers.

CM, Pérez-Rodríguez M, Pérez-de-laCruz AJ, Gil Á. A new fructose-free, resistant-starch type IV-enriched enteral formula improves glycaemic control and cardiovascular risk biomarkers when administered for 6 weeks to elderly diabetic patients. AbstractBackground: Reducing the dietary glycaemic response has been proposed as a way to reduce the risk of diabetes complications. Objective: The aim of the present study was to evaluate the glycaemic control and cardiovascular risk biomarkers in fragile, elderly type 2 diabetes patients after the intake of a new fructose-free diabetes-specifi c formula enriched with resistant-starch type IV and high in monounsaturated fatty acids. Methods: Forty-one type 2 diabetes patients aged 78.9 ± 2.8 years were fed exclusively with an enteral diabetes-specifi c formula for 6 weeks. Data were collected at baseline and after 6 weeks of feeding. Carbohydrate and lipid metabolism and infl ammatory and cardiovascular risk biomarkers were measured to evaluated the course of diabetes complications. Results: Blood glycated haemoglobin signifi cantly decreased after the intervention (6.1 ± 0.1 vs. 5.8 ± 0.1 %; p < 0,045), as well as monocyte chemotactic protein-1 and soluble E-selectin (p < 0.05), while soluble vascular cell adhesion molecule and plasminogen activator inhibitor-1 tended to decrease from baseline to 6 weeks (p = 0.084 and p = 0.05, respectively). Conclusion:The new product improves glycaemic control and cardiovascular risk without altering lipid metabolism, which is useful for the prevention of diabetic complications. Longer intervention studies are needed in order to validate these results in a larger population.

BackgroundDietary intake during metabolic trials has been controlled using one or another assessment method. The luxury of comparison of mutual results is rarely available.ObjectiveTo compare data between self‐reported nutrient intake from 24‐h recall and FFQ at baseline among overweight and obese Spanish participants in a metabolic trial.Methods151 volunteers (age 18–65 y) were enrolled in a randomized, placebo‐controlled, double‐blind, crossover trial. Subjects were interviewed by 2 standardized nutritionists in a baseline 24‐h recall and a FFQ.ResultsAt a group level, median FFQ‐derived energy was estimated as higher than that with 24h‐recall (2600 vs 1874 kcal) as were carbohydrates (273 vs 206 g), proteins (117 vs 87 g) and fats (116 vs 81 g), respectively. All differences were significant at p<0.05. At the individual level, 83% of subjects reported more energy on FFQ and 17% more on 24‐h recall interviews. Regarding macronutrients, 77% of subjects for carbohydrates, 81% for protein and 84% for fat reported greater intakes with the FFQ approach.ConclusionAs expected, results from this study indicate that FFQ overestimated dietary intake in comparison to the 24‐h recall.This trial is registered at clinicaltrials.gov as NCT01290250 and it is funded by The Coca‐Cola Company.